Akari Therapeutics (NASDAQ:AKTX) Share Price Passes Below Two Hundred Day Moving Average – Here’s Why

Akari Therapeutics, Plc (NASDAQ:AKTX) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.14 and traded as low as $0.95. Akari Therapeutics shares last traded at $0.99, with a volume of 29,967 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Akari Therapeutics in a research report on Saturday. They set a “sell” rating on the stock.

Akari Therapeutics Price Performance

The business has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $2.14.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.